Search Results 101-110 of 27408 for Two-phase

  1. Expediting Patient Identification of LGI1-IgG Autoimmune Encephalitis for Enrollment into Phase 2 Study - Mayo Clinic

    The purpose of this study is to expedite patient identification of LGI1-IgG autoimmune encephalitis patients for enrollment in the UCB sponsored phase 2 study ...

  2. A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma - Mayo Clinic

    Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose axitinib in patients with ...

  3. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy - Mayo Clinic

    The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well ...

  4. Renal Cell Carcinoma Clinical Trials - Mayo Clinic Research

    Mayo Clinic will be participating in both Part A (Phase 1) & (Phase 2) B of the study. ... The study consists of two stages: in the Dose Escalation Stage ...

  5. Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis - Mayo Clinic

    The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo. Participation eligibility. Participant eligibility includes age ...

  6. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

    A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors. Print details. Share; Facebook · Twitter.

  7. A Study to Evaluate the Combination of Margetuximab, Retifanlimab, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer - Mayo Clinic

    A Study to Evaluate the Combination of Margetuximab, Retifanlimab, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer · Overview · Participation ...

  8. A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer - Mayo Clinic

    This is a Phase 1/2 trial to evaluate the safety, tolerability and efficacy of FG-3019 administered with gemcitabine and Nab-paclitaxel in the treatment of ...

  9. A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence - Mayo Clinic

    A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated ...

  10. A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies - Mayo Clinic

    A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in ...